Severe community acquired pneumonia update: mortality, mechanisms and medical intervention
Citation:
Critical Care
2008
12(Suppl 6):S1
Volume 12 Supplement 6
Severe community-acquired pneumonia update: mortality, mechanisms and medical intervention
Proceedings
Edited by Steven Opal
Publication of this supplement has been sponsored by Novartis.
Severe community-acquired pneumonia update: mortality, mechanisms, and medical intervention.
Barcelona, Spain21 April 2008
-
-
Demographics, guidelines, and clinical experience in severe community-acquired pneumonia
Mortality in patients with community-acquired pneumonia (CAP) who require intubation or support with inotropes in an intensive care unit setting remains extremely high (up to 50%). Systematic use of objective ...
Citation: Critical Care 2008 12(Suppl 6):S2 -
Tissue factor as an initiator of coagulation and inflammation in the lung
Patients with severe infections almost invariably exhibit evidence of activation of the coagulation system. The lungs are amongst the most frequently affected organs during severe infection and sepsis. The abu...
Citation: Critical Care 2008 12(Suppl 6):S3 -
Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition
Despite effective antibiotic therapy, about one-third of patients admitted to an intensive care unit (ICU) with severe community-acquired pneumonia (CAP) and organ dysfunction die within a month. This high dea...
Citation: Critical Care 2008 12(Suppl 6):S4 -
The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy
Patients with community-acquired pneumonia (CAP) in the hospital setting exhibit markedly abnormal levels of various biomarkers of infection, inflammation and coagulation. CAP is a well characterized disease, ...
Citation: Critical Care 2008 12(Suppl 6):S5
Follow
- ISSN: 1364-8535 (electronic)